FTC Pauses Its Efforts to Block Amgen $27.8B Purchase of Horizon Therapeutics

Amgen scored a win in its bid to acquire Horizon Therapeutics with the FTC withdrawing from adjudication of its challenge of the deal until Sept. 18, to allow for discussion of a possible settlement.
Source: Drug Industry Daily

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.